My Treatment Approach: HER2+ Metastatic Breast Cancer - Integrating Emerging Data and Evolving Therapeutic Strategies
In this video series, we’ll discuss complex patient case scenarios in HER2-positive metastatic breast cancer, exploring current standards of care, emerging clinical data, and evolving therapeutic strategies. Our goal is to provide practical, evidence-based insights to help clinicians navigate treatment sequencing, manage toxicities, and apply the latest research, such as findings from DESTINY-Breast09 and upcoming SABCS patient-reported outcomes, to optimize outcomes for patients with HER2+ disease. Editorial note: This program was recorded prior to the FDA approval of fam-trastuzumab deruxtecan-nxki in combination with pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer. Discussion reflects the clinical data, regulatory status, and treatment considerations available at the time of filming. For additional context on the recent FDA approval, view our related OncLive editorial coverage: FDA Approves T-DXd Plus Pertuzumab for HER2+ Breast Cancer | OncLive
Advertisement
My Treatment Approach: HER2+ Metastatic Breast Cancer - Integrating Emerging Data and Evolving Therapeutic Strategies
This opening segment sets the clinical foundation for the program by reviewing how treatment paradigms for HER2 positive metastatic breast cancer have evolved in recent years. The discussion introduces current guideline supported first line standards of care and highlights how the incorporation of antibody drug conjugates has expanded therapeutic possibilities beyond traditional chemotherapy and monoclonal antibody combinations. Panelists reflect on how these advances have reshaped long term disease management by improving response depth and extending disease control for many patients. Attention is also given to real world implementation, with comparison of adoption patterns across academic and community practices. Factors such as familiarity with novel agents, comfort managing ADC and TKI associated toxicities, and access to infusion resources are explored as drivers of variation in first line treatment selection. This segment establishes a practical framework for understanding how evolving evidence translates into everyday clinical decision making for patients with HER2 positive disease.
This segment highlights the interim topline efficacy findings from DESTINY Breast09 and explores their potential implications for first-line treatment of HER2 positive metastatic breast cancer. The discussion summarizes progression-free survival signals observed with trastuzumab deruxtecan with or without pertuzumab compared with the historical standard regimen of docetaxel, trastuzumab, and pertuzumab. Panelists emphasize that these results represent an early data readout and should be interpreted cautiously pending peer-reviewed publication, mature follow-up, and formal guideline integration. The conversation focuses on how these findings may challenge existing first-line paradigms by introducing an antibody drug conjugate earlier in the disease course, while reinforcing the importance of contextualizing DB09 within the broader HER2 evidence base. This segment sets the stage for subsequent discussion on safety, durability of benefit, and how emerging data may ultimately influence clinical practice once fully validated.
Experts discuss innovative strategies in breast cancer treatment, exploring induction maintenance and optimal response approaches for improved patient outcomes.
Explore the complexities of treating HER2-positive breast cancer with CNS involvement after T-DXd therapy, focusing on innovative approaches and outcomes.
Experts discuss the complexities of treatment sequencing in cancer therapy, highlighting the importance of patient-reported outcomes and drug efficacy.
Explore the latest insights on biomarkers and emerging therapies for HER2-positive metastatic breast cancer, highlighting future research opportunities.
